Chemokine gene expression signatures including CCL5, CXCL9, CXCL10, and CXCL11 were reported that could accurately predict anti-PD-1 immunotherapy response for patients with head and neck squamous cell carcinoma and gastric cancer [18]. Here, CXCL9 is linked to gastric cancer.